Yonsei Med J.  2008 Oct;49(5):783-791. 10.3349/ymj.2008.49.5.783.

Gender-specific Association between Polymorphism of Vascular Endothelial Growth Factor (VEGF 936C>T) Gene and Patients with Stomach Cancer

• Bae SJ
• Ahn DH
• Hong SP
• Kang H
• Hwang SG
• Oh D
• Kim NK

• KMID: 2158197
• DOI: http://doi.org/10.3349/ymj.2008.49.5.783

Abstract

PURPOSE
Angiogenesis plays an important role in the growth, progression, and metastasis of tumors. Vascular endothelial growth factor (VEGF) overexpression has been associated with advanced stage and poor survival in several cancers. We investigated the present case-control study to determine whether there is an association between the VEGF 936C>T polymorphism and stomach cancer. PATIENTS AND METHODS: The association of functional single nucleotide polymorphisms (SNPs) of the VEGF gene with stomach cancer development was evaluated in a case-control study of 154 Korean stomach cancer patients. Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. RESULTS: Our results revealed significant association of T allele-bearing genotypes with increased risk for stomach cancer development. Genotype frequencies of the VEGF 936C>T polymorphisms were significantly different between patient and control groups (CT, AOR: 2.007, 95% CI: 1.277-3.156, TT, AOR: 4.790, 95% CI: 1.174-19.539, CT+TT, AOR: 2.147, 95% CI: 1.382-3.337). When stratified by gender and age, genotype frequencies were significantly different for stomach cancer in women and in patients younger than 55 years (in women, CT, OR: 3.049, 95% CI: 1.568-5.930, CT+TT, OR: 3.132, 95% CI: 1.638-5.990; in < 55 years, CT, OR: 3.306, 95% CI: 1.413-7.732, CT+TT, OR: 3.967, 95% CI: 1.729-9.104). In addition, this association partially remained in cases with intestinal and diffuse-type stomach cancer. CONCLUSION: Our present study suggests that the VEGF 936C>T polymorphism is a susceptibility factor for stomach cancer, at least in Korean. These observations, however, require further confirmation by a larger multi-ethnic study.

Keyword

Stomach cancer; polymorphism; vascular endothelial growth factor; Korean

MeSH Terms

Adult
Aged
Aged, 80 and over
Case-Control Studies
Female
Genotype
Humans
Male
Middle Aged
*Polymorphism, Genetic
Sex Factors
Stomach Neoplasms/*genetics
Vascular Endothelial Growth Factor A/*genetics

Reference

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005. 55:74–108.

2. Kong U, Koo J, Choi K, Park J, Chang H. The expression of GAGE gene can predict aggressive biologic behavior of intestinal type of stomach cancer. Hepatogastroenterology. 2004. 51:1519–1523.

3. Yasui W, Ito H, Yoshida K, Tahara E. Biological malignancy in human gastric carcinoma--molecular aspects. Gan To Kagaku Ryoho. 1991. 18:927–933.

4. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer. 1995. 75(6 Suppl):1418–1425.

5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003. 9:669–676.

6. Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res. 2005. 11:3647–3653.

7. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 2004. 46:293–298.

8. Ferrara N. Vascular endothelial growth factors as a target for anticancer therapy. Oncologist. 2004. 9:Suppl 1. 2–10.

9. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002. 2:795–803.

10. Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q, et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res. 2005. 65:5015–5019.

11. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995. 55:3964–3968.

12. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res. 1994. 85:1045–1049.

13. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993. 53:4727–4735.

14. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993. 143:1255–1262.

15. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 1994. 54:276–280.

16. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996. 77:858–863.

17. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000. 12:1232–1235.

18. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000. 183:S1–S22.

19. Vauhkonen M, Vauhkonen H, Sipponen P. Pathology and molecular biology of gastric cancer. Best Pract Res Clin Gastroenterol. 2006. 20:651–674.

20. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer. 2003. 106:468–471.

21. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003. 34:383–394.

22. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002. 62:3369–3372.

23. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 2002. 13:260–264.

24. Tzanakis N, Gazouli M, Rallis G, Giannopoulos G, Papaconstantinou I, Theodoropoulos G, et al. Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol. 2006. 94:624–630.

25. Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT, et al. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev. 2006. 15:1148–1152.

26. Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, et al. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006. 8:R22.

27. Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine. 2006. 35:21–28.

28. Abe A, Sato K, Habuchi T, Wang L, Li Z, Tsuchiya N, et al. Single nucleotide polymorphisms in the 3' untranslated region of vascular endothelial growth factor gene in Japanese population with or without renal cell carcinoma. Tohoku J Exp Med. 2002. 198:181–190.

29. Vauhkonen M, Vauhkonen H, Sipponen P. Pathology and molecular biology of gastric cancer. Best Pract Res Clin Gastroenterol. 2006. 20:651–674.

30. Sciacca FL, Ciusani E, Silvani A, Corsini E, Frigerio S, Pogliani S, et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res. 2004. 10:1312–1317.

31. Eroglu A, Gulec S, Akar N. Vascular endothelial growth factor C936T polymorphism in cancer patients with thrombosis. Am J Hematol. 2006. 82:174.

32. Pinedo HM. The role of VEGF in oncology: effects on hemostasis and thrombosis. Pathophysiol Haemost Thromb. 2003. 33:Suppl 1. 11–12.

33. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood. 2000. 96:4216–4221.

34. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphism in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum Immunol. 1999. 60:1245–1249.

35. Yapijakis C, Vairaktaris E, Vassiliou S, Vylliotis A, Nkenke E, Nixon AM, et al. The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer. J Cancer Res Clin Oncol. 2007. 133:787–791.

36. Bae SJ, Kim JW, Kang H, Hwang SG, Oh D, Kim NK. Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936C > T) gene and colon cancer in Korea. Anticancer Res. 2008. 28:1271–1276.

37. Sakao S, Tatsumi K, Hashimoto T, Igari H, Shino Y, Shirasawa H, et al. Vascular endothelial growth factor and the risk of smoking-related COPD. Chest. 2003. 124:323–327.

38. Butt C, Lim S, Greenwood C, Rahman P. VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis. BMC Musculoskelet Disord. 2007. 8:1.

39. Günesacar R, Opelz G, Erken E, Pelzl S, Döhler B, Ruhenstroth A, et al. VEGF 936 C/T gene polymorphism in renal transplant recipients: association of the T allele with good graft outcome. Hum Immunol. 2007. 68:599–602.

40. Clark AG. The role of haplotypes in candidate gene studies. Genet Epidemiol. 2004. 27:321–333.